news
Expansion of the global antibiotics market size
The global antibiotics market is set to increase at a CAGR of 4 percent to $62.06 billion, due to the rising prevalence of infectious diseases...
List view / Grid view
Novartis
news
Sales of generic oncology drugs surge
A report has forecasted that the generic oncology drugs market could register an impressive 6 percent CAGR up to the year 2028...
news
Late-stage pipeline drugs could compete with only treatment for SMA
A number of drugs currently in their late stages in the development process could see competition for nusinersen, the only current SMA treatment, rise...
news
NHS announces groundbreaking personalised child cancer treatment
The NHS has announced a groundbreaking new treatment, CAR-T, for children with leukaemia...
news
Aimovig approved by EU for migraine prevention
Researchers found that more than one quarter (26 per cent) of patients taking Aimovig 70mg were migraine free after month 15...
news
FDA approves the inclusion of new evidence for Cosentyx in PsA
The FDA has approved the inclusion of new evidence that Cosentyx significantly slows the progression of joint structural damage..
news
FDA expands approval of Gilenya to treat multiple sclerosis in paediatric patients
The FDA has approved Gilenya to treat relapsing multiple sclerosis in children and adolescents age 10 years and older...
news
Novartis invests $100 mn to eliminate malaria
Novartis is to invest more than $ 100 million to advance research and development of new antimalarials over the next five years...
news
Novartis forms alliance to develop medicines for cryptosporidiosis
Novartis and the Bill & Melinda Gates Foundation have formed an alliance to advance the development of Novartis' drug candidate KDU731...
news
FDA approves Glatopa a generic option for relapsing forms of multiple sclerosis
Sandoz has announced that the FDA has approved and launch of Glatopa as a fully-substitutable, AP-rated generic version of Copaxone for relapsing forms of MS...
news
Promacta receives Breakthrough Therapy designation for SAA
The FDA has granted Breakthrough Therapy designation to Promacta for use in combination with standard immunosuppressive therapy for severe aplastic anaemia...
news
Kisqali receives breakthrough therapy designation for advanced breast cancer
Kisqali receives breakthrough therapy designation for initial endocrine-based treatment of pre- or perimenopausal women with HR+/HER2- advanced or metastatic breast cancer...
news
Sandoz proposed biosimilar pegfilgrastim accepted by EMA
Sandoz has announced that its biosimilar pegfilgrastim has been accepted by the EMA for regulatory review...
news
Revolade shows long-term disease control for immune thrombocytopenia
Novartis has announced long-term study results supporting the positive safety and efficacy of Revolade in adults with chronic/persistent immune thrombocytopenia...
news
Novartis announces new CEO
Novartis announces CEO Joseph Jimenez to retire from Novartis in 2018. Vasant Narasimhan appointed CEO, effective February 1, 2018.
